doxazosin has been researched along with Cardiometabolic Syndrome in 8 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
Cardiometabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of the present study was to explore the effect of carvedilol treatment on metabolic parameters in patients with metabolic syndrome." | 9.12 | The effect of carvedilol on metabolic parameters in patients with metabolic syndrome. ( Oguz, A; Uzunlulu, M; Yorulmaz, E, 2006) |
| "In patients with the metabolic syndrome, doxazosin treatment not only decreases platelet activity, as measured by a change in MPV, but also improves metabolic abnormalities." | 9.12 | Effects of doxazosin and amlodipine on mean platelet volume and serum serotonin level in patients with metabolic syndrome: a randomised, controlled study. ( Basar, M; Demirtunc, R; Duman, D, 2007) |
| "To evaluate the vascular effects of doxazosin, an alpha-1 antagonist, in hypertensive patients with metabolic syndrome in whom the drug has previously been shown to exert beneficial metabolic actions on lipids and insulin metabolism." | 7.73 | The vascular effects of doxazosin in hypertension complicated by metabolic syndrome. ( Del Prato, S; Dell'Omo, G; Pedrinelli, R; Pellegrini, G; Penno, G; Pucci, L; Scotti, A, 2005) |
| "Treatment with doxazosin positively influenced the metabolic profile." | 5.31 | [Hypertension and metabolic syndrome in population of one company. Monotherapy with amlodipine and doxazosin]. ( Ceremuzyński, L; Cybulski, J, 2002) |
| "The objective of the present study was to explore the effect of carvedilol treatment on metabolic parameters in patients with metabolic syndrome." | 5.12 | The effect of carvedilol on metabolic parameters in patients with metabolic syndrome. ( Oguz, A; Uzunlulu, M; Yorulmaz, E, 2006) |
| "In patients with the metabolic syndrome, doxazosin treatment not only decreases platelet activity, as measured by a change in MPV, but also improves metabolic abnormalities." | 5.12 | Effects of doxazosin and amlodipine on mean platelet volume and serum serotonin level in patients with metabolic syndrome: a randomised, controlled study. ( Basar, M; Demirtunc, R; Duman, D, 2007) |
| "To evaluate the vascular effects of doxazosin, an alpha-1 antagonist, in hypertensive patients with metabolic syndrome in whom the drug has previously been shown to exert beneficial metabolic actions on lipids and insulin metabolism." | 3.73 | The vascular effects of doxazosin in hypertension complicated by metabolic syndrome. ( Del Prato, S; Dell'Omo, G; Pedrinelli, R; Pellegrini, G; Penno, G; Pucci, L; Scotti, A, 2005) |
| "Insulin resistance was measured by homeostasis assessment index (HOMA)." | 2.73 | Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. ( Acikel, C; Caglar, K; Celik, T; Eyileten, T; Oguz, Y; Sonmez, A; Vural, A; Yavuz, I; Yenicesu, M; Yilmaz, MI, 2007) |
| "Treatment with doxazosin positively influenced the metabolic profile." | 1.31 | [Hypertension and metabolic syndrome in population of one company. Monotherapy with amlodipine and doxazosin]. ( Ceremuzyński, L; Cybulski, J, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (87.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, YC | 1 |
| Liu, CC | 1 |
| Juan, YS | 1 |
| Wu, WJ | 1 |
| Li, WM | 1 |
| Yeh, HC | 1 |
| Wang, CJ | 1 |
| Huang, CN | 1 |
| Huang, CH | 1 |
| Huang, SP | 1 |
| Cybulski, J | 1 |
| Ceremuzyński, L | 1 |
| Dell'Omo, G | 2 |
| Penno, G | 2 |
| Pucci, L | 1 |
| Pellegrini, G | 1 |
| Scotti, A | 1 |
| Del Prato, S | 2 |
| Pedrinelli, R | 2 |
| Uzunlulu, M | 1 |
| Oguz, A | 1 |
| Yorulmaz, E | 1 |
| Yilmaz, MI | 1 |
| Sonmez, A | 1 |
| Caglar, K | 1 |
| Celik, T | 1 |
| Yenicesu, M | 1 |
| Eyileten, T | 1 |
| Acikel, C | 1 |
| Oguz, Y | 1 |
| Yavuz, I | 1 |
| Vural, A | 1 |
| Demirtunc, R | 1 |
| Duman, D | 1 |
| Basar, M | 1 |
| Wright, JT | 1 |
| Harris-Haywood, S | 1 |
| Pressel, S | 1 |
| Barzilay, J | 1 |
| Baimbridge, C | 1 |
| Bareis, CJ | 1 |
| Basile, JN | 1 |
| Black, HR | 1 |
| Dart, R | 1 |
| Gupta, AK | 1 |
| Hamilton, BP | 1 |
| Einhorn, PT | 1 |
| Haywood, LJ | 1 |
| Jafri, SZ | 1 |
| Louis, GT | 1 |
| Whelton, PK | 1 |
| Scott, CL | 1 |
| Simmons, DL | 1 |
| Stanford, C | 1 |
| Davis, BR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Valsartan Versus Amlodipine Effect on Left Ventricular Multidirectional Deformation and Adipocytokines Level in Hypertensive Patients: Speckle Tracking Echocardiography[NCT03990480] | Phase 4 | 230 participants (Actual) | Interventional | 2018-12-01 | Completed | ||
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for doxazosin and Cardiometabolic Syndrome
| Article | Year |
|---|---|
Doxazosin in metabolically complicated hypertension.
Topics: Adrenergic alpha-Antagonists; Clinical Trials as Topic; Diet, Sodium-Restricted; Dose-Response Relat | 2007 |
4 trials available for doxazosin and Cardiometabolic Syndrome
| Article | Year |
|---|---|
The effect of carvedilol on metabolic parameters in patients with metabolic syndrome.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Anthropometry; Antihypertensive Ag | 2006 |
Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome.
Topics: Adiponectin; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers | 2007 |
Effects of doxazosin and amlodipine on mean platelet volume and serum serotonin level in patients with metabolic syndrome: a randomised, controlled study.
Topics: Amlodipine; Antihypertensive Agents; Blood Platelets; Doxazosin; Female; Humans; Male; Metabolic Syn | 2007 |
Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Black People; Chlorthalidone; Double-B | 2008 |
3 other studies available for doxazosin and Cardiometabolic Syndrome
| Article | Year |
|---|---|
The impact of metabolic syndrome on the responsiveness to α1-blocker in men with BPH/LUTS.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Doxazosin; Humans; Lower Ur | 2013 |
[Hypertension and metabolic syndrome in population of one company. Monotherapy with amlodipine and doxazosin].
Topics: Adult; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Doxazosin; Fem | 2002 |
The vascular effects of doxazosin in hypertension complicated by metabolic syndrome.
Topics: Dose-Response Relationship, Drug; Doxazosin; Drug Administration Schedule; Endothelium, Vascular; Fo | 2005 |